Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 14, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding their interests in the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of specific share transactions rather than a financial performance report.
Material Changes
The filing details the acquisition of Ordinary Shares by four individuals (Mr. J S Heslop, Mr. R Bondy, Mr. D Learmouth, and Mr. A P Witty) on September 11, 2006. Each individual acquired 9 shares through the personal contribution element and 9 shares through the company matching element of the ShareReward Plan. The purchase price was GBP 14.79 per Ordinary Share.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document strictly adheres to Disclosure Rules 3.1.4R(1)(a) and 3.1.4R(1)(b) regarding director share transactions.
Investor Verification Points
- Verify the share price of GBP 14.79 per Ordinary Share on September 11, 2006.
- Confirm the total number of shares acquired by each named director (18 shares per person: 9 personal, 9 matched).
- Review the terms of the ShareReward Plan entered into on October 5, 2001, to understand the matching contribution structure.
- Check subsequent filings for any further changes in director shareholdings.